These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 19100899

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sirolimus: a ten-year perspective.
    Kahan BD.
    Transplant Proc; 2004; 36(1):71-5. PubMed ID: 15013304
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus: a current perspective.
    Yakupoglu YK, Kahan BD.
    Exp Clin Transplant; 2003 Jun; 1(1):8-18. PubMed ID: 15859902
    [Abstract] [Full Text] [Related]

  • 4. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M.
    Transplant Proc; 2008 Jun; 40(6):1858-61. PubMed ID: 18675070
    [Abstract] [Full Text] [Related]

  • 5. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 9. Where did we leave off in 2008? Conclusions from the 8th International Symposium.
    Russ G.
    Transplant Proc; 2009 Nov 15; 41(6 Suppl):S27-30. PubMed ID: 19651292
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sirolimus-based immunosuppression: present state of the art.
    Kahan BD.
    J Nephrol; 2004 Nov 15; 17 Suppl 8():S32-9. PubMed ID: 15599884
    [Abstract] [Full Text] [Related]

  • 12. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar 15; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 13. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM, Kobashigawa J, Klintmalm G.
    Clin Transplant; 2008 Mar 15; 22(1):1-15. PubMed ID: 18217899
    [Abstract] [Full Text] [Related]

  • 14. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I, Chan L.
    Transplant Proc; 2011 Mar 15; 43(2):472-7. PubMed ID: 21440737
    [Abstract] [Full Text] [Related]

  • 15. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 15; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 16. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B.
    Transplant Rev (Orlando); 2009 Jan 15; 23(1):47-52. PubMed ID: 19027616
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
    Hymes LC, Warshaw BL.
    Pediatr Transplant; 2005 Aug 15; 9(4):520-2. PubMed ID: 16048606
    [Abstract] [Full Text] [Related]

  • 18. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
    Alamo JM, Barrera L, Casado MD, Bernal C, Marin LM, Suarez G, Sanchez-Moreno L, Jimenez R, Suarez-Grau JM, Sousa JM, Cordero E, Gomez-Bravo MA.
    Transplant Proc; 2009 Aug 15; 41(6):2181-3. PubMed ID: 19715866
    [Abstract] [Full Text] [Related]

  • 19. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul 15; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 20. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.